Spots Global Cancer Trial Database for metastatic solid tumors
Every month we try and update this database with for metastatic solid tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | NCT06364696 | Solid Tumor | ASP4396 | 18 Years - | Astellas Pharma Inc | |
| INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | NCT03589651 | Unresectable or... | Retifanlimab Epacadostat INCB050465 | 18 Years - | Incyte Corporation | |
| Imaging of Advanced Tumours Using [131]I-IAZA | NCT03427320 | Locally Advance... Metastatic Soli... | [131]I-IAZA | 18 Years - 75 Years | University of Alberta | |
| A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors | NCT03910530 | Advanced Solid ... Metastatic Soli... | Retifanlimab INCB001158 Retifanlimab + ... | 18 Years - | Incyte Corporation | |
| A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study | NCT04010240 | Metastatic Soli... | Retrospective c... | 1 Month - | Institut Bergonié | |
| Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | NCT05853367 | Metastatic Soli... Advanced Solid ... | MK-0472 Pembrolizumab MK-1084 | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03646071 | Locally Advance... Metastatic Soli... | RX108 | 18 Years - | NeuPharma, Inc. | |
| Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | NCT02610075 | Locally Advance... Metastatic Soli... Ovarian Cancer | AZD1775 | 18 Years - 130 Years | AstraZeneca | |
| PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | NCT05639751 | Advanced Solid ... Metastatic Soli... Non-small Cell ... SMARCA4 Gene Mu... | PRT3789 Docetaxel | 18 Years - | Prelude Therapeutics | |
| Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors | NCT02281409 | Advanced Solid ... Metastatic Soli... | Mogamulizumab (... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | NCT02817633 | Neoplasms | TSR-022 Nivolumab TSR-042 TSR-033 Docetaxel Pemetrexed Cisplatin Carboplatin | 18 Years - | Tesaro, Inc. | |
| Imaging of Advanced Tumours Using [131]I-IAZA | NCT03427320 | Locally Advance... Metastatic Soli... | [131]I-IAZA | 18 Years - 75 Years | University of Alberta | |
| Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors | NCT02313012 | Neoplasm Metast... | CC-90003 | 18 Years - | Celgene | |
| Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | NCT02610075 | Locally Advance... Metastatic Soli... Ovarian Cancer | AZD1775 | 18 Years - 130 Years | AstraZeneca | |
| A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors | NCT00907205 | Advanced or Met... Cancer Solid Cancers | SF1126 | 18 Years - | Semafore Pharmaceuticals | |
| Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | NCT05853367 | Metastatic Soli... Advanced Solid ... | MK-0472 Pembrolizumab MK-1084 | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | NCT00876122 | Non-Hodgkin's L... | GDC-0941 | 18 Years - | Genentech, Inc. | |
| Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors | NCT00793897 | Advanced Solid ... Metastatic Soli... | BMS-754807 Paclitaxel Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| Stem Cell Transplantation for Metastatic Solid Tumors | NCT00001880 | Neoplasm Metast... | methotrexate Cyclosporin | 10 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors | NCT02715284 | Neoplasms | Dostarlimab | 18 Years - | Tesaro, Inc. | |
| A Study of DCC-2701 in Participants With Advanced Solid Tumors | NCT02228811 | Locally Advance... Metastatic Soli... Cancers With ME... Cancers With TR... | DCC-2701 tablet | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study | NCT04010240 | Metastatic Soli... | Retrospective c... | 1 Month - | Institut Bergonié | |
| A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | NCT00876122 | Non-Hodgkin's L... | GDC-0941 | 18 Years - | Genentech, Inc. | |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | NCT02045602 | Locally Advance... Metastatic Soli... Pancreatic Aden... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| Study of CHS-114 in Participants With Advanced Solid Tumors | NCT05635643 | Advanced Solid ... Head and Neck S... | CHS-114 toripaliamab | 18 Years - | Coherus Biosciences, Inc. | |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | NCT05238922 | Solid Tumors | INCB0123667 | 18 Years - | Incyte Corporation | |
| A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors | NCT00827203 | Metastatic Soli... | Elesclomol Sodi... | 18 Years - | Synta Pharmaceuticals Corp. | |
| First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors | NCT05494918 | Advanced Solid ... Metastatic Soli... | JSKN003 | 18 Years - | Alphamab (Australia) Co Pty Ltd. | |
| Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors | NCT02235688 | Metastatic Soli... | aldoxorubicin aldoxorubicin aldoxorubicin gemcitabine | 15 Years - 80 Years | ImmunityBio, Inc. | |
| A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors | NCT03854227 | Advanced Solid ... Metastatic Soli... | PF-06939999 dos... PF-06939999 mon... PF-06939999 in ... | 18 Years - | Pfizer | |
| A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | NCT03059823 | Locally Advance... Metastatic Soli... | retifanlimab | 18 Years - | Incyte Corporation | |
| This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | NCT03573544 | Metastatic Soli... Locally Advance... | OBI-888 OBI-888 Globo H IHC Ass... | 18 Years - | OBI Pharma, Inc | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT06031441 | Locally Advance... Recurrent Solid... Metastatic Soli... | RO7566802 Atezolizumab | 18 Years - | Genentech, Inc. | |
| A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors | NCT02869295 | Unspecified Adu... | NKTR-214 | 18 Years - | Nektar Therapeutics | |
| Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute | NCT03098576 | Cancer | Matched targete... Unmatched stand... | 18 Years - | Cedars-Sinai Medical Center | |
| A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation | NCT00405327 | Sarcoma Neuroblastoma Wilm's Tumor | Tumor lysate-pu... Hematopoietic s... | - 30 Years | University of Michigan Rogel Cancer Center | |
| A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors | NCT05996445 | Solid Tumors | XmAb662 Keytruda® (pemb... | 18 Years - | Xencor, Inc. | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT02867007 | Solid Tumor Cancer Carcinoma | KHK2455 Mogamulizumab | 18 Years - | Kyowa Kirin Co., Ltd. | |
| A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | NCT00876109 | Solid Cancers | GDC-0941 | 18 Years - | Genentech, Inc. | |
| Study of CHS-114 in Participants With Advanced Solid Tumors | NCT05635643 | Advanced Solid ... Head and Neck S... | CHS-114 toripaliamab | 18 Years - | Coherus Biosciences, Inc. | |
| Study of SRF617 in Patients With Advanced Solid Tumors | NCT04336098 | Advanced Solid ... | SRF617 Gemcitabine Albumin-Bound P... Pembrolizumab | 18 Years - | Surface Oncology | |
| A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | NCT06364696 | Solid Tumor | ASP4396 | 18 Years - | Astellas Pharma Inc | |
| Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) | NCT00670488 | Locally Advance... Metastatic Soli... Cancer Neoplasms | MK-2206 | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | NCT02610075 | Locally Advance... Metastatic Soli... Ovarian Cancer | AZD1775 | 18 Years - 130 Years | AstraZeneca | |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors | NCT01928459 | Advanced Solid ... Metastatic Soli... | BGJ398 BYL719 | 18 Years - | Novartis | |
| This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | NCT03573544 | Metastatic Soli... Locally Advance... | OBI-888 OBI-888 Globo H IHC Ass... | 18 Years - | OBI Pharma, Inc | |
| Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | NCT03388632 | Metastatic Soli... Treatment-Refra... | rhIL-15 Ipilimumab Nivolumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | NCT05836324 | Solid Tumors Advanced Solid ... Metastatic Soli... | INCA33890 | 18 Years - | Incyte Corporation | |
| A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors | NCT05381909 | Solid Tumor, Ad... | BGB-24714 Paclitaxel Carboplatin Docetaxel | 18 Years - | BeiGene | |
| A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors | NCT01847118 | Advanced Solid ... Metastatic Soli... | Sevacizumab | 18 Years - 74 Years | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00492830 | Cancer Neoplasm Metast... | TRC093 recombin... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| First in Human Study of M6223 | NCT04457778 | Metastatic Soli... | M6223 Bintrafusp alfa M6223 | 18 Years - | EMD Serono | |
| M1231 in Participants With Solid Tumors | NCT04695847 | Metastatic Soli... Esophageal Canc... Non-Small Cell ... | M1231 M1231 | 18 Years - | EMD Serono | |
| A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | NCT03059823 | Locally Advance... Metastatic Soli... | retifanlimab | 18 Years - | Incyte Corporation | |
| Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer | NCT01449370 | Metastatic Soli... | TAK-117 | 18 Years - | Takeda | |
| A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03071757 | Advanced Solid ... | ABBV-368 ABBV-181 | 18 Years - | AbbVie | |
| A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors | NCT02869295 | Unspecified Adu... | NKTR-214 | 18 Years - | Nektar Therapeutics | |
| Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors | NCT00148993 | Metastatic Soli... | Tumor Cell Vacc... | 18 Years - | Hadassah Medical Organization | |
| A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03071757 | Advanced Solid ... | ABBV-368 ABBV-181 | 18 Years - | AbbVie | |
| Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | NCT04374877 | Advanced Solid ... Clear Cell Rena... Hepatocellular ... Non-small Cell ... | CHS-388 Pembrolizumab Toripalimab | 18 Years - | Coherus Biosciences, Inc. | |
| A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies | NCT00162500 | Multiple Myelom... Tumors | Peptide Vaccine... | 18 Years - | Hadassah Medical Organization | |
| To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors | NCT01922752 | Solid Tumors | CEP-37440 | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Stem Cell Transplantation for Metastatic Solid Tumors | NCT00001880 | Neoplasm Metast... | methotrexate Cyclosporin | 10 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of ASP1012 in Adults With Solid Tumors | NCT06171178 | Solid Tumor | ASP1012 Pembrolizumab | 18 Years - | Astellas Pharma Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
